Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04992949
Other study ID # CPX-351 TA-SMP
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 23, 2022
Est. completion date September 1, 2025

Study information

Verified date October 2022
Source French Innovative Leukemia Organisation
Contact Valérie ROLLAND-NEYRET
Phone (0)4 76 76 50 96
Email VRolland-neyret@chu-grenoble.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The three classic myeloproliferative neoplasms (MPNs) include polycythemia Vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The natural history of these MPNs is the possible progression to acute myeloid leukemia (MPN-blast phase) at variable percentage depending the entity. Leukemic transformation of MPN occurs in 8% to 23% of primary myelofibrosis (PMF) patients in the first 10 years after diagnosis and in 4% to 8% of polycythemia vera (PV) and essential thrombocytosis (ET) patients within 18 years after diagnosis. The risk for leukemic transformation is increased by exposure to cytotoxic chemotherapy. The molecular pathogenesis of MPN-blast phase remains an area of active research. The prognosis of blast phase MPNs is very poor : approximately 50% of the patients are deemed eligible for intensive treatment (ie. conventional induction chemotherapy regimen with anthracyclines and cytarabine). The patients who are not fit for such intensive treatment approach due to age or comorbidities, are treated with Hypomethylating agents, low dose palliative chemotherapy, or supportive care. Nevertheless, there is a need for more effective and better tolerated treatment approaches in order to increase the response rate and hence, the transplant rates which should translate into improved survival. CPX-351 is a new formulation of cytarabine and daunorubicin encapsulated at a fixed 5:1 molar-ratio in liposomes that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy. Based on similarities between post-myelodysplastic syndrome (MDS) and post-MPN secondary AML in terms of disease resistance to chemotherapy, of fragile patient profile, The hypotheses made is that CPX-351 may improve the results of induction chemotherapy without increasing its toxicity and therefore may increase the proportion of patients who could benefit from an allogeneic Stem Cell Transplantation (SCT).


Description:

The primary objective of the study is to evaluate the Complete Remission (CR/CRi) rate after treatment with CPX-351 in patients with AML secondary to myeloproliferative neoplasms (post-MPN AML). The hypotheses made is that treatment with CPX-351 will improve the historical response rate from 45% to 65%. The exact single stage Phase II design was used to calculate the number of patients. The null hypothesis H0 is that the probability p of CR/CRi rate with CPX351 is equal or lower than the historical rate p0 of 45% (H0: p≤p0). The alternative hypothesis H1 that is p>p0, supposing that CR/CRi rate will be 65% using CPX351. Considering an alpha risk of 5% and a power of 80%, 42 patients will be included, and H0 will be rejected if at least 25 patients achieve CR /CRi (R-project, "clinfun" package). Inclusion period : 36 months Treatment period (6 months) : - one or two cycles of induction treatment with CPX-351 (depending on CR/CRi achieving). If CR/CRi is not achieved following the induction phase, patients will go off study. - 2 courses of consolidation therapy with CPX-351 (patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle) All included patients will be followed for 60 days after the End of Treatment (EOT) or at the date of allogeneic stem cell transplantation when appropriate : the day-60 follow-up visit will be the End Of Study (EOS) visit. The anti-leukemic chemotherapy administrated after relapse will be recorded. After completion of the study, subjects will be followed-up at regular intervals (every 3 months) to collect information on the subjects' survival and disease (relapse) status. Survival status will be collected until death, or withdrawal of consent or lost to follow-up, whichever occurs first..


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date September 1, 2025
Est. primary completion date July 21, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of newly secondary AML according to WHO 2016 classification following an antecedent of Myeloproliferative Neoplasm including Essential Thrombocythemia (ET), Polycythemia Vera (PV), primary or secondary Myelofibrosis - Performance status 2 Eastern Cooperative Oncology Group (ECOG) grading. - Eligible for standard intensive chemotherapy - Absence of concomitant severe cardiovascular disease which would make intensive chemotherapy impossible, i.e. arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease, reduced left ventricular function assessed by multigated acquisition (MUGA) scan or echocardiogram. Cardiac ejection fraction = 50% by echocardiography ou MUGA - Patient must have adequate organ function as indicated by the following laboratory values: - Renal - Serum creatinine: < 2 mg/dl OR calculated creatinine clearance*: = 30 mL/min by MDRD formula for patients with creatinine levels > 1.5 X institutional Upper Limit Normal (ULN) - Hepatic - Serum total bilirubin: = 2.5 X ULN OR direct bilirubin = ULN for patients with total bilirubin levels = 2 mg/dL unless Gilbert's Syndrome - Aspartate-Amino-Transferase (ASAT) and Alanine-Transaminase (ALAT): = 2.5 times ULN - Alkaline Phosphatase: = 5 X ULN, if > 2.5 X ULN, then liver fraction should be = 2.5 X ULN *Creatinine clearance should be calculated per institutional standard - Life expectancy should be of 12 weeks at least according to investigator evaluation - Female patients of childbearing potential must have a negative serum pregnancy test (ß-hCG) within 72 hours prior to receiving the first dose of CPX-351. Female patients who are not post-menopausal, free from menses for > 2 years or surgically sterilized, will have to use adequate barrier methods of contraception to prevent pregnancy or agree to abstain from becoming pregnant throughout the study, starting with Visit 1. - Male patients agree to use an adequate method of contraception for the duration of the study. Men should be advised not to father a child while receiving CPX-351 and for 3 months post study. - Patients have the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study. Exclusion Criteria: - MPN/MDS mixed types - Prior therapy for AML transformation except for Hydroxyurea - Prior treatment with growth factors such as erythropoietin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF), low-dose oral chemotherapy or Hypomethylating agents chemotherapy given in the chronic phase of MPN in the 30 days before inclusion, except for hydroxyurea. - Uncontrolled undercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance. - Active and uncontrolled infection - Current participation or participation in a study with an investigational compound or device within 30 days of initial dosing with study drug - Patients with acute promyelocytic leukemia. - Known human immunodeficiency virus (HIV) infection or HIV-related malignancy - Clinically active hepatitis B or hepatitis C infection. - Known allergy or hypersensitivity to any component of CPX-351. - Currently active second malignancy, other than non-melanoma skin cancer and in situ carcinoma of the cervix. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for >3 years or are considered by their physician to be at less than 30% risk of relapse - Clinical evidence of Central Nervous System Leukemia. - Pregnancy or breastfeeding during the projected duration of the study.

Study Design


Intervention

Drug:
CPX-351
Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course. Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle

Locations

Country Name City State
France AMIENS - CHU Amiens Picardie Amiens
France ANGERS - CHU - Maladies du sang Angers
France AVIGNON - Centre Hospitalier Avignon
France BAYONNE - CH de la Côte Basque - Hématologie Bayonne
France AVICENNE - Centre de Recherche Clinique Bobigny
France BREST - Hôpital Morvan Brest
France CAEN - CHU Caen - IHBN Caen
France CLAMART - Hôpital d'Instruction des Armées de Percy Clamart
France Clermont-Ferrand - Chu Estaing Clermont-Ferrand
France CRETEIL - CHU Henri Mondor Créteil
France Grenoble - CHUGA - Hématologie Clinique Grenoble
France LILLE CHU - Hôpital Claude Huriez Lille
France LIMOGES - CHU Dupuytren 1 Limoges
France LYON-Centre Léon Bérard Lyon
France MARSEILLE - Institut Paoli-Calmettes Marseille
France MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique Montpellier
France NANTES - Hôpital Hôtel Dieu - Hématologie Clinique Nantes
France NICE - Centre Antoine Lacassagne Nice
France NICE - CHU - Hopital Archet 1 Nice
France NIMES - CHU Caremeau Nîmes
France ORLEANS - CHR - Hématologie Orléans
France Paris Saint Louis Paris
France Paris St Antoine Paris
France BORDEAUX - Hôpital Haut-Levêque Pessac
France LYON HCL - CH Lyon Sud Pierre-Bénite
France POITIERS - Hôpital La Milétrie - Hématologie Clinique Poitiers
France REIMS - Hôpital Robert Debré - Hématologie Clinique Reims
France RENNES - Hôpital Pontchaillou - Hématologie Rennes
France Strasbourg - Icans Strasbourg
France Toulouse - IUCT Oncopole - Service d'Hématologie Toulouse
France TOURS - Hôpital Bretonneau Tours
France NANCY - CHU de Brabois Vandœuvre-lès-Nancy
France VERSAILLES - Hôpital André Mignot Versailles
France Institut Gustave Roussy Villejuif

Sponsors (3)

Lead Sponsor Collaborator
French Innovative Leukemia Organisation Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes

Country where clinical trial is conducted

France, 

References & Publications (2)

Courtier F, Carbuccia N, Garnier S, Guille A, Adélaïde J, Cervera N, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Chaffanet M, Birnbaum D, Murati A. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica. 2017 Jan;102(1):e11-e14. doi: 10.3324/haematol.2016.152363. Epub 2016 Oct 14. — View Citation

Luque Paz D, Jouanneau-Courville R, Riou J, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887-4897. Blood Adv. 2020 Nov 24;4(22):5651. doi: 10.1182/bloodadvances.2020003711. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of CR/CRi after first induction therapy Rate of CR/CRi according to ELN2017 criteria After 28 to 42 days after one cycle of 5 days of CPX351
Primary Rate of CR/CRi after second induction therapy Rate of CR/CRi according to ELN2017 criteria If applicable, after 28 to 31 days after a second cycle of 3 days of CPX351
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2